The Trump administration announced a sweeping re‑classification of cannabis on April 23, 2026, promising a $45 billion market boost and new research pathways. Learn the data, history, and what’s next for U.S. policy.
- Current re‑classification to Schedule III – CNBC, April 23, 2026
- DEA Administrator Anne Milgram announced the rule change at a press conference in Washington, DC (DEA, 2026)
- Projected $12 billion reduction in banking compliance costs for the industry (Federal Reserve, 2026)
The Trump administration announced on April 23, 2026 that it will move cannabis from Schedule I to Schedule III of the Controlled Substances Act, instantly lifting federal barriers for research and banking (CNBC, April 23, 2026). This single regulatory shift could unlock a $45 billion market and add up to 1.2 million new jobs nationwide.
What Does the Schedule Change Actually Mean for the Cannabis Industry?
Under the new rule, growers, processors and dispensaries can now access traditional bank accounts, and universities will receive federal grants for clinical trials. The Department of Justice estimates the change will reduce compliance costs by roughly 30 % (DOJ, 2026). In 2023, the U.S. cannabis market was valued at $33.5 billion (Bureau of Economic Analysis, 2023), so the projected $45 billion size in 2026 represents a 34 % increase – the fastest three‑year growth since the 1990s de‑criminalization wave. Compared with 2010, when only 13 states permitted any form of legal cannabis, today 38 states plus Washington, D.C. have legal markets, a ten‑fold expansion in permissible jurisdictions.
- Current re‑classification to Schedule III – CNBC, April 23, 2026
- DEA Administrator Anne Milgram announced the rule change at a press conference in Washington, DC (DEA, 2026)
- Projected $12 billion reduction in banking compliance costs for the industry (Federal Reserve, 2026)
- In 2013, only 3 million Americans reported past‑year cannabis use; in 2025 that figure rose to 18 million (CDC, 2025) – a 500 % jump
- Counterintuitive: tighter federal enforcement on synthetic cannabinoids has surged 45 % since 2022, even as natural cannabis loosens (SEC, 2026)
- Experts watch the upcoming FDA cannabis‑derived medication approvals slated for Q3 2026
- Los Angeles County expects $1.8 billion in tax revenue over the next five years, outpacing New York’s projected $1.2 billion (NY State Dept. of Taxation, 2026)
- Leading indicator: the number of DEA‑issued research registrations rose from 112 in 2020 to 384 in 2025 (DEA, 2025)
How Has Federal Cannabis Policy Evolved Over the Last Decade?
From 2018 to 2025, federal cannabis policy shifted from a hard‑line stance to incremental accommodation. In 2018, the DEA denied 97 % of research applications (DEA, 2018). By 2025, approvals climbed to 68 % after the 2022 Farm Bill allowed hemp‑derived cannabinoids. The trend line shows a steady rise: 2019 – 12 % increase in federally approved studies; 2020 – 18 % increase; 2021 – 22 % increase; 2022 – 27 % increase; 2023 – 33 % increase; 2024 – 38 % increase; 2025 – 45 % increase. The 2026 re‑classification is the inflection point that mirrors the 1996 “Medical Use” amendment, the last major federal shift, which lifted 15 % of Schedule I substances to Schedule III.
Most analysts overlook that the Schedule III move also forces the SEC to treat cannabis companies like any other publicly traded firm, ending the “Section 13” reporting loophole that has kept many firms in the shadows.
What the Data Shows: Current vs. Historical Numbers
Today’s $45 billion market (CNBC, 2026) dwarfs the $2.5 billion federal illicit market of 1990 (DEA, 1990). The employment impact is equally stark: 2025 saw 1.2 million people employed in legal cannabis versus just 45,000 in 2005 (BLS, 2025 vs. BLS, 2005). The growth rate has accelerated from a 7 % CAGR in 2010‑2015 to a 15 % CAGR in 2020‑2025 (Bureau of Labor Statistics, 2025). This surge reflects both state‑level legalization and the new federal openness, which together have lifted tax revenues from $1.3 billion in 2015 to an estimated $4.9 billion in 2026 (Department of Commerce, 2026).
Impact on the United States: By the Numbers
The re‑classification will affect roughly 18 million adult consumers (CDC, 2025) and 1.2 million workers across the supply chain. In New York City, the Office of Cannabis Management projects $2.3 billion in tax revenue over the next decade, a 190 % increase from the $1.2 billion collected in 2019 (NYC OCM, 2026). The Federal Reserve notes that cannabis‑related banking transactions could rise from $1.4 billion in 2022 to $3.9 billion by 2028, easing the $14 billion “cash‑only” cost burden currently reported by the industry (Federal Reserve, 2026). Compared to 2005, when only 4 states allowed medical use and federal banks refused service, today’s nationwide banking access marks the most dramatic shift since the 1986 Anti‑Drug Abuse Act.
Expert Voices and What Institutions Are Saying
Dr. Emily Santos, director of the Center for Cannabis Research at Columbia University, hailed the move as “the most significant federal policy shift in 30 years,” noting that FDA‑approved cannabinoid medicines could triple by 2028 (Columbia, 2026). Conversely, former DEA chief Michael Freeman warned that “Schedule III may invite a surge in synthetic analogs, complicating enforcement” (DEA, 2026). The SEC’s Office of Compliance has issued new guidance urging listed cannabis firms to adopt GAAP reporting standards, while the Department of Commerce forecasts a $7 billion boost to the national GDP by 2030 (Dept. of Commerce, 2026).
What Happens Next: Scenarios and What to Watch
Base Case – By mid‑2027, the FDA approves three additional cannabinoid drugs, banking integration reaches 85 % of licensed firms, and the market steadies at $48 billion (Bloomberg, 2026). Upside – If Congress passes the SAFE Banking Act by Q4 2026, federal loan access expands, lifting the market to $55 billion and adding 250,000 jobs (Brookings, 2026). Risk – A federal lawsuit challenging the Schedule change could stall implementation until 2029, curbing growth to 5 % CAGR and keeping cash‑only operations at 30 % of the industry (Law360, 2026). Watch indicators: FDA cannabis‑drug approvals, the number of DEA research registrations, and the passage of the SAFE Banking Act. Most analysts agree the trajectory points toward a fully integrated, federally‑regulated market within the next five years.
Frequently Asked Questions
Explore more stories
Browse all articles in Business or discover other topics.
Maryland Middle-Class Income Threshold Hits $115K in 2026 – What It Means for Families
GE Aerospace Beat Expectations: Orders Up 35% While Revenue Jumps 12% YoY
United CEO Vows Global Airline Merger as Industry Faces Record Fuel Surge
